Cantor Fitzgerald analyst Steve Seedhouse last night initiated coverage of Wave Life Sciences (WVE) with an Overweight rating and $10 price target Wave develops oligonucleotide therapeutics using various mechanistic approaches across diverse indications, the analyst tells investors in a research note. The firm says the company’s emerging preclinical RNA editing programs illustrate power and versatility of its approach.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences initiated with an Overweight at Cantor Fitzgerald
- JPMorgan biotech/Euro pharma analysts hold analyst/industry conference call
- RBC sees Makary interview as potentially positive for biotech stocks
- Wave Life Sciences price target lowered to $19 from $22 at B. Riley
- Wedbush starts RNA-focused standout Wave Life Sciences with an Outperform